Reviewer’s report

Title: Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in nonsmall cell lung cancer patients (HANSHIN 0316)

Version: 0 Date: 29 Jul 2018

Reviewer: Hidehito Horinouchi

Reviewer's report:

Authors reported summary of clinical course of patients who was not able to continue immune checkpoint inhibitors because of adverse events. This manuscript contains important information which might be shared as practical clinical question by readers of BMC Cancer. As I understand the clinical relevance of this manuscript and would like to ask some revisions.

Comments

1) Because the number of patients included in this analysis was small, we should be cautious to generalize the observations. It would be better to provide detailed information of each patients participated this analysis. Please consider add table which contains characteristics and clinical course of each participants. For example, the table would be informative if it contains patients' age, histology, treatment line, number of cycles he or she received immune check point inhibitors, objective response, type of adverse events and duration of progression free survival.

2) As survival analyses, I would like to ask authors to add spider's plot information about response to immune checkpoint inhibitors.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have nothing declare.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal